Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.

MyLotus beginning to blossom (CPT)     

kimoldfield - 08 Aug 2016 11:38

Chart.aspx?Provider=EODIntra&Code=CPT&Si

Frontier Resources (AIM:FRI), agreed to acquire Concepta Diagnostics Limited (“Concepta”), a pioneering UK healthcare company established in 2013, that has developed proprietary products and a platform, which targets the personalised mobile health market with a primary focus on women’s fertility and specifically unexplained infertility. SPARK Advisory Partners is acting as Nominated Adviser and Financial Adviser to the Company with Beaufort Securities as Broker.

This acquisition has been completed, FRI is now CPT

From RNS 26.7.2016:- "Mercia Technologies PLC (AIM: MERC), which is focused on the creation, funding and scaling of innovative businesses with high growth potential from the UK regions, is delighted to announce the successful admission of the enlarged share capital of Concepta PLC ("Concepta", AIM: CPT), one of its direct portfolio companies formerly named Concepta Diagnostics Ltd, to trading on AIM at 8.00am today."


http://www.conceptaplc.com/concepta/about-us
Concepta's flagship product MyLotus has a unique offering, allowing women to see YES / NO results as well as their actual and personal level of factors that can have a direct influence on fertility – MyLotus is the only home-test on the market that currently offers this.

MyLotus has the ability to quantify personal hormone levels enabling the identification of the fertile period for a large number of women, especially for the significant amount of women whose hCG and LH levels vary from mean levels.

Bullshare - 09 Aug 2016 09:00 - 2 of 35

I have bought a few today.


M

kimoldfield - 09 Aug 2016 09:15 - 3 of 35

The sp can only go up now then! :o)

Bullshare - 09 Aug 2016 12:57 - 4 of 35

If it goes down I wil blame you , of course!!! :-)

kimoldfield - 09 Aug 2016 13:11 - 5 of 35

My shoulders are broad Mike! :o)

dreamcatcher - 09 Aug 2016 17:39 - 6 of 35

Don't go near anything kim is in. lol

kimoldfield - 09 Aug 2016 23:23 - 7 of 35

Very sound advice lol! :o)

kimoldfield - 28 Aug 2016 12:53 - 8 of 35

Mail on Sunday's Midas column has apparently tipped the shares to go far, not that it should influence anyone! :o)

Bullshare - 30 Aug 2016 11:46 - 9 of 35

Seems to be blue today !!!

kimoldfield - 30 Aug 2016 12:16 - 10 of 35

Top sliced, next stop £20 by close. 😀

Bullshare - 30 Aug 2016 15:53 - 11 of 35

£1 by Xmas

kimoldfield - 30 Aug 2016 16:49 - 12 of 35

Nooooo, as little as that?! :o)

kimoldfield - 30 Aug 2016 16:50 - 13 of 35

Which one?

dreamcatcher - 30 Aug 2016 16:55 - 14 of 35

Well done all. :-))

Bullshare - 31 Aug 2016 14:03 - 15 of 35

Its blue again today, well done kimoldfield, when shall we sell ;-0)

dreamcatcher - 31 Aug 2016 16:31 - 16 of 35

When kim does.lol

kimoldfield - 31 Aug 2016 17:25 - 17 of 35

Already have! :o)

dreamcatcher - 31 Aug 2016 17:27 - 18 of 35

They will rocket now. :-))

kimoldfield - 31 Aug 2016 17:28 - 19 of 35

Well, not entirely, sold enough for a profit and a nice holding of free shares! I will be buying again on any dip in price; of course it may not happen if they are going to £1 by Xmas!

kimoldfield - 31 Aug 2016 17:30 - 20 of 35

Yes DC, if they do it will be your fault! :o)

dreamcatcher - 31 Aug 2016 17:30 - 21 of 35

Beware kim still holds. lol

kimoldfield - 31 Aug 2016 17:31 - 22 of 35

Lol! You have been warned! :o)

dreamcatcher - 31 Aug 2016 17:37 - 23 of 35

Well done,

Bullshare - 01 Sep 2016 09:58 - 24 of 35

I'm still in but getting twitchy!

Bullshare - 01 Sep 2016 10:28 - 25 of 35

Steve; I have just PM'ed you via MoneyAM.

M

kimoldfield - 01 Sep 2016 11:10 - 26 of 35

Thanks Mike, I have replied!

SP possibly at top for this week!

Bullshare - 12 Sep 2016 09:32 - 27 of 35

Sold out today, got 18.95p. Steve, again thanks for this one:-)

kimoldfield - 12 Sep 2016 11:04 - 28 of 35

My pleasure Mike! Keep an eye on it, more to come at some point.

Bullshare - 12 Sep 2016 12:41 - 29 of 35

I will probably let it retrace a bit then get back in.

kimoldfield - 26 Sep 2016 08:16 - 30 of 35

RNS Number : 7527K
Concepta PLC
26 September 2016


Concepta plc ("Concepta" or the "Company")
Chinese Manufacturing Agreement Signed with Shijiazhuang Huanzhong Biotech Limited 


Concepta plc (AIM:CPT), the UK healthcare company targeting the personalised mobile health market with a primary focus on women's fertility, announces that it has signed a Manufacturing Agreement ('the Agreement') with Shijiazhuang Huanzhong Biotech Limited ('HZ Biotech'), a leading Chinese manufacturer with operations in Shijiazhuang, to assemble and package Concepta's 'My Lotus' fertility product. This Agreement is in line with the Company's strategy as it builds towards the launch of its My Lotus product for unexplained infertility* into China in H2 2016.

Under the terms of the Agreement, HZ Biotech will exclusively assemble and package Concepta produced components (including bulk tests and electronic meters), to produce Concepta's My Lotus product to specification for the Chinese market. HZ will utilise its manufacturing site and processes, adhering to locally applicable laws and Chinese regulatory requirements. In addition to assembling the final My Lotus product, HZ Biotech will be the sole purchaser of Concepta's My Lotus product and help facilitate its launch to the Chinese market and include post-market surveillance. Concepta will also look to work with a network of distributors in China to help achieve maximum market penetration in China and will update the market on these developments in due course.

Concepta's MyLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

Commenting on the Agreement, Erik Henau, Concepta CEO said: "I am delighted to announce this agreement with leading Chinese manufacturer HZ Biotech, which marks a significant step for Concepta towards the launch of our 'My Lotus' fertility product into China in 2016. With regulatory approvals already in place in China, the Chinese market represents a highly attractive initial launch market for Concepta. An estimated 4 million women in China each year discover that they have unexplained infertility. The sheer scale of the target market, combined with a growing Chinese middle class for whom our My Lotus product is affordable and recent regulatory changes regarding the one-child policy, all create the conditions for an exceptional market opportunity. As such annual revenue potential for this target market is expected to be worth £250m per annum.

"We look forward to updating the market on our progress with HZ Biotech as we roll out our flagship fertility product in our first international market with the UK and Europe targeted for 2017."

kimoldfield - 09 Jan 2017 13:44 - 31 of 35

Progress is slow but at least it is progress!

Concepta achieves ISO13485 accreditation for its myLotus fertility product ahead of targeted commercial launch in the UK and Europe in H2 2017

Concepta plc (AIM:CPT), the UK healthcare company targeting the personalised mobile health market with a primary focus on women's fertility, is pleased to announce that it has achieved ISO13485 accreditation, a key step in attaining its CE marking for its 'myLotus' product for unexplained infertility*, ahead of a commercial launch in the UK and Europe in H2 2017.

The ISO13485 certification is an endorsement of the Quality Management System (QMS) that underpins the Company's position as a manufacturer of medical devices. The accreditation is recognised on an international scale and is a critical part of gaining regulatory approval for Concepta's myLotus to be sold in the European Union.

Commenting on the agreement, Erik Henau, CEO of Concepta said: "This is a proud moment for the Concepta team and importantly a crucial development towards the launch of our flagship myLotus fertility product into the UK and European markets, where the potential market opportunity is circa £350 million.

"It cannot be underestimated how much work goes into documenting the procedures of an entire organisation within a QMS system and ensuring that the procedures are followed to the point that they become a seamless part of everyday operations. It is a strong endorsement of the quality of an organisation at all levels.

"Further to this we are delighted to report that with regulatory approvals and manufacturing agreements already in place in China we remain on track to roll out the myLotus product into the Chinese market in H1 2017."

kimoldfield - 23 Aug 2017 13:29 - 32 of 35

Slow progress but progress nevertheless.

Corporate update.

opman - 23 Aug 2017 20:46 - 33 of 35

CORPORATE UPDATE

Wed 23 Aug 2017 12:00
RNS Number : 7958O
Concepta PLC
23 August 2017

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR)

23 August 2017

Concepta plc
("Concepta" or the "Company")
CORPORATE UPDATE

Concepta makes first shipment of myLotus fertility product to China

Founding member of Company appointed Head of China Operations

Concepta plc (AIM: CPT) the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility, is pleased to provide a positive update regarding its marketing and sales drive into China of its myLotus fertility product.

Following the receipt of its first sales order, totalling £225,000, for its myLotus fertility product from its partner in China, HuanZhong Biotech Co.Ltd (see announcement 13 June 2017), the Company has made its first shipment of products to China. As part of this first shipment, the Company scaled up production of its test strips at its UK manufacturing site in Sharnbrook, Bedfordshire, allowing it to shorten its lead-time for shipment by two weeks. The Company expects to make further regular shipments to fulfil this order in the coming weeks.
The Company is also pleased to announce that it has appointed Zhang Zhi Gang, as Head of China Operations. Zhang was one of the founders of Concepta Diagnostics Limited and led the way in developing key contacts in China for manufacturing and distribution. Zhang has extensive knowledge of the Chinese healthcare market. Her previous position was as General Manager at Alere China Co. Ltd ("Alere"). During her time at Alere she helped launch 8 new products and managed 5 product lines. Previously to this Zhang was at Unipath UK where she helped develop the patented algorithms currently used by Clearblue's range of fertility and pregnancy test products.

Zhang is currently managing a hospital evaluation process for Concepta to support the use of myLotus products for early pregnancy monitoring. This application is of particular importance in China, where the use of myLotus is seen as an opportunity to reduce the overwhelming number of hospital appointments and offer a better way to manage the early pregnancy period. This will extend the potential application of myLotus to a considerable number of pregnancies each year across China.
Erik Henau, CEO says: "We are pleased to have made our first shipment of test strips to China, and particularly pleased to have done so with such a quick turnaround time, testament to the quality of operations at our UK laboratory.

"We are also extremely pleased that Zhang Zhi Gang has taken on this important role in our Chinese operation, she will be an important part of the next phase of Concepta's Chinese launch. The response thus far from Chinese doctors has been very positive and the additional evaluation to support early pregnancy monitoring is underway.

"We have been working hard behind the scenes to engage our raw material suppliers to receive stocks within quoted lead times. In parallel there is particular attention to the application of our Quality System and its stringent Quality Assurance standards. We continue to work closely with our Chinese partners to assemble the approved products prior to our launch of products into hospitals in China. We look forward to keeping our shareholders informed on our progress in China with regular announcements over the coming months."

Enquiries:

Concepta plc
Adam Reynolds, Chairman / Erik Henau, CEO
Tel: +44 (0) 7785 908158 / +44 (0) 7557 985479

SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550

Beaufort Securities Limited (Broker)
Jon Belliss
Tel: +44 (0)20 7382 8300

Yellow Jersey PR Limited (Financial PR)
Felicity Winkles / Joe Burgess/ Katie Bairsto
Tel: +44 (0) 7748 843 871

About Concepta Plc:
Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

Founded in 2013, Concepta has developed a revolutionary flagship product 'myLotus' for home self-testing that helps women with unexplained infertility to conceive.

myLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

Concepta has a defined route to market for its new 'myLotus' product with Regulatory approvals for launch in China in place for H1 2017 and CE-Marking for UK and Europe to follow later in 2017. The revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.


This information is provided by RNS
The company news service from the London Stock Exchange

END

opman - 19 Sep 2017 07:40 - 34 of 35

Promising Interim Statement with some tangible progress being made and more in the pipeline.


Tue 19 Sep 2017 07:00
RNS Number : 0642R
Concepta PLC
19 September 2017


19 September 2017

Concepta plc ("Concepta" or the "Company")
Interim Results

Concepta plc (AIM: CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility, announces its interim results for the six months to 30 June 2017.

Operational Highlights
· Continuing to progress flagship myLotus fertility product towards market launch in China and Europe
· Signed the first distributor agreement in China with Beijing ThinkBrio Medical Technology Consulting Co Ltd ("ThinkBrio")
· First myLotus sales order of £225,000 received from HuanZhong Biotech Co Ltd ("HZ Biotech")
· First shipment of myLotus products from UK production sent to China as part of first sales order to HZ Biotech
· Appointed founding member of Concepta, Zhang Zhi Gang, as Head of China Operations
· Achieved ISO13485 accreditation for myLotus for commercial launch in UK and Europe
· Signed technology transfer agreement with Selective Antibodies to develop stress test for myLotus fertility product
· Appointed Neil Mesher, CEO of Philips (UK and Ireland), as Non Executive Director

Financial Position
· Cash balance at the period end was £1,234,974 (H1 2016 £341,249)
· Loss for the period of £1,083,905 (H1 2016 £414,589)
· Cash outlay for Doncaster factory facilities and equipment was £512,686

Chairman's Statement

I am pleased to report Concepta's half year results for the six months to 30 June 2017. During this period, the Company has made significant inroads towards the launch of its flagship myLotus product in China and towards setting up the infrastructure and resources, both in the UK and China, to support the future scale-up of production and sales.

We have been working hard on the complex process of moving from laboratory prepared product to ISO 13485 certified production facilities and the fit out of the new manufacturing facility in Doncaster, UK has been progressing well. The recruitment of site management and staff, and the installation of equipment, and associated infrastructure has resulted in the expectation that the new facilities in Doncaster will be fully operational by the end of 2017. During this period, limited production has been facilitated at our Colworth site and the first product for sale has been shipped to China.

In addition to preparation for the launch of our myLotus fertility product in China, the on-going process of achieving CE marking for Europe continues, with clinical and stability trials starting in September 2017. The CE marking accreditation is expected to be achieved by the end of 2017, allowing the launch of myLotus into the UK and German markets in the first half of 2018.

Whilst having made significant progress towards commercial launch in both China and in Europe of our myLotus product, some of the key milestones in our development towards these goals during the period have been slower to materialise than expected and this was highlighted in our June statement. These related to changes to the Chinese regulatory framework on health apps, which necessitated additional development work and a delay in our new Doncaster facility becoming fully operational. However, post the period end, both of these issues have been dealt with and we have seen a significant increase in enquiries from various new potential distributors in China and we will keep shareholders fully informed with progress.

Our primary focus during the period has been on the preparation for scale up and production of myLotus, we have also been busy with the development of new products to complement our myLotus range. This includes a stress test, which enables users to monitor stress through quantitative measurement of their levels of stress hormones, of which cortisol is the key one. This new product development has been progressed by utilising the resources of Selective Antibodies, following the technology transfer and licence agreement we signed and announced on 7 February 2017. The development of this new product will take several years to bring to market, but as it extends the product range, it will support ongoing growth in future years.

To support our future plans, the Board of Directors has also been strengthened with the appointment of Neil Mesher, CEO of Philips UK & Ireland, who has brought his significant experience and industry knowledge to contribute to our strategic planning process.

Financial review

· The Group's total comprehensive loss for the six months to 30 June 2017 was £1,083,905 (30 June 2016 £414,589)
· The basic and diluted loss per share was £(0.01) (six months to 30 June 2016 £(0.01)
· Cash balance as at 30 June 2017 was £1,234,974 (30 June 2016 £341,249)

During the period, tight cost control has been implemented and finance facilities for the plant and equipment required for the Doncaster factory has been agreed.

As the Company is at an early stage of development, it is not anticipated that there will be sufficient earnings arising in the short term that will enable the Board to make the recommendation or pay any dividends.

Outlook

Concepta is focused on delivering immediate milestones that are linked to the manufacture, marketing and sales of the initial myLotus product offering in the fertility area. The potential of the myLotus platform playing a role in the shift towards Personalised Health is being recognised outside of the Company and we have started to explore the opportunities and to match them to the requirements that will be linked to the rate of growth.

The immediate focus is the launch of myLotus in China and the CE marking to allow its launch into Europe. Following on from the progress in the first half of 2017, the Company expects to achieve both these objectives by the first half of next financial year and in turn begin to generate revenues for the Company. The certification of the Doncaster production facility is expected to be complete by the end of 2017 and to support the planned manufacturing scale up, David Darrock will be joining the Company as Site Manager (COO designate). David has significant experience in the full manufacturing processes in this industry.

Whilst our initial product offering is focused on helping women to conceive, we are currently running a hospital evaluation process in China to extend the use of the myLotus product into early pregnancy monitoring, as there is a very high demand for information on the healthy progression of the pregnancy in the early stages. Depending on the results, the potential application of the product would be utilised by up to 18 million births per year in China and would increase our opportunities to add this product to every market we launch into. Additionally, it would create an additional earnings stream for the Group, and the benefits would be demonstrated during the 2018 financial year.

The transition from a start-up to a fully operational company is always a challenging one. However, despite delays to the initial launch of our myLotus product, I believe that we have made positive progress over the period, laying the foundations required for ongoing rapid growth and, in turn, a successful myLotus product launch and penetration into the Chinese and European markets by the end of this year and 2018 respectively.

Adam Reynolds
Chairman

**ENDS**

opman - 23 Oct 2017 08:25 - 35 of 35

Concepta gives positive update on myLotus in China

StockMarketWire.com

Concepta has announced a positive update on the launch of its proprietary myLotus product in its first international market, China.

The company has signed an additional two three-year exclusive distribution agreements for myLotus with Huanzhong Biotech and Wanma Technology Co in China.

The distribution agreement with Huanzhong Biotech Ltd will cover the province of Hebei near Beijing, while Wanma Technology Co will cover the Shanghai area.

It said: 'Alongside ThinkBrio, which distributes the myLotus product to Beijing and Lianoing, these two agreements will expand Concepta's product offering in China to target a total population of 147 million people across these regions.'

Concepta also said it had completed a preliminary hospital evaluation process in China to extend the use of myLotus into early pregnancy monitoring.

It said:'Based on recent positive hospital evaluation results, the Company's new distributors, Huanzhong Biotech Ltd and Wanma Technology will be the first to target the "early pregnancy" group alongside the "unexplained infertility" target group.

'There is a total target market of 2.3 million women a year across the Hebei, Beijing, Lianoing and Shanghai areas for early pregnancy monitoring.'

Chief executive Erik Henau said: 'We are delighted to add these new distributors to our network in China, following the Company's excellent preliminary hospital evaluation results.

'Following the final conclusion of the evaluation, an event will be held in China for a large number of potential distributors where we will exhibit the myLotus product.

'We expect to announce further distribution agreement signings following this event.'

At 9:46am: (LON:CPT) Concepta Plc Ord 2.5p share price was +0.75p at 10p


Story provided by StockMarketWire.com
Register now or login to post to this thread.